
Fluent Corp.
CNTMF • Drug Manufacturers - Specialty & Generic
$0.02
▲ +0.00 (+3.77%)
Current price
EarningsLatest report: Dec 31, 2025
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$15.41M
Growth
—
Cash Flow
2/5
Trend
Volatile
Evidence
Weak liquidity · 0.34Negative growth trendWeak profitability
Financial data as of: Dec 31, 2025, 12:00 AM UTCLast earnings update: Dec 31, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.02
Change3.77%
Shares Out700.55M
Market Cap$15.41M
Enterprise Value$79.41M
52W Range0.02 - 0.09
Beta0.85
P/E-0.21
P/S0.18
P/B-0.19
P/FCF-1.05
EV/Sales0.92
Price$0.02
Change3.77%
Shares Out700.55M
Market Cap$15.41M
Enterprise Value$79.41M
52W Range0.02 - 0.09
Beta0.85
P/E-0.21
P/S0.18
P/B-0.19
P/FCF-1.05
EV/Sales0.92
EV/EBITDA-3.02
EV/FCF-5.43
Earnings Yield-470.39%
FCF Yield-94.91%
Dividend Yield0.00%
Gross Margin32.38%
Oper. Margin-17.57%
Profit Margin-83.63%
Debt/Eq-1.73
Current Ratio0.34
Quick Ratio0.16
Volume274.64K
Avg Volume464.71K
EPS Surprise-0.04
Investment DNA
How strong this company looks for long-term investors
40
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
20/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Weak liquidity · 0.34Negative growth trendWeak profitability
Analyst view
No analyst data available now.
Financial Health
Score4 / 20
Debt / Equity: -1.73
Current Ratio: 0.34
Quick Ratio: 0.16
Status: HighRisk
Warnings
- Weak Liquidity
- Weak quick ratio
🧾
No insider activity
No recent insider transactions available.
